CHICAGO, IL, USA (UroToday.com) - This study assessed the use of NMP22 to predict which high-risk superficial bladder cancer patients will have recurrence, progression or disease-related death and compared this to standard urine cytology.
Your session will expire in 8 hours requiring you to log in each day to view content.